Loading
The 2007 population study of 6,370 Californian women that fixed the demographics of triple-negative breast cancer: younger, more often Black or Hispanic, poorer, diagnosed later and with worse survival at every stage; Black women with late-stage disease had 14 percent five-year survival.
Bauer, Brown, Cress, Parise and colleagues used California Cancer Registry data to identify women diagnosed with triple-negative breast cancer between 1999 and 2003 and compared 6,370 triple-negative cases with 44,704 other breast cancers by age, race and ethnicity, socioeconomic status, stage, grade and relative survival. Women with triple-negative cancers were more likely to be under 40 (odds ratio 1.53), non-Hispanic Black (1.77) or Hispanic (1.23). Regardless of stage, they had poorer survival than women with other breast cancers, and non-Hispanic Black women with late-stage triple-negative disease had the poorest survival of any group, a five-year relative survival of 14 percent.
The first registry-scale description of the disparity that every later triple-negative disparity paper confirms; the phrase so-called triple-negative phenotype in the title marks the moment the term entered population science.
The most recent national figure behind the statement that Black women in the United States have about twice the incidence of triple-negative breast cancer; trial enrolment has not matched it.
Explains why triple-negative trials can use three-year event-free survival, why follow-up is front-loaded, and why survivors past five years are told their risk has largely passed.
Shares Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Close the gap between who gets triple-negative breast cancer and who is in its trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.